Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib + Decitabine in Advanced MPN
NCT05524857Phase 1Terminated
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fedratinib in Myeloproliferative Neoplasm (MPN) and myeloproliferative neoplasm blast phase (BP-MPN) (2 arms). Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Jan 2022; status: terminated.
02
Drugs
fedratinib
03
Conditions
Myeloproliferative Neoplasm (MPN)myeloproliferative neoplasm blast phase (BP-MPN)
Beyond the preview
Go deeper on NCT05524857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524857.